肥満:治療薬開発パイプライン分析

◆英語タイトル:Obesity - Pipeline Review, H2 2017
◆商品コード:GMDHC9914IDB
◆発行会社(調査会社):Global Markets Direct
◆発行日:2017年11月21日
◆ページ数:518
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD5,000 ⇒換算¥550,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD7,500 ⇒換算¥825,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、世界における肥満の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。
・イントロダクション
・肥満の概要
・肥満治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・肥満パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・企業別、開発中の製品
・大学/研究機関別、研究中の製品
・肥満治療薬開発に取り組んでいる企業:企業別製品パイプライン
・肥満治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Obesity – Pipeline Review, H2 2017

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Obesity – Pipeline Review, H2 2017, provides an overview of the Obesity (Metabolic Disorders) pipeline landscape.

Obesity is defined as having an excessive amount of body fat. Obesity increases risk of diseases and health problems such as heart disease, diabetes and high blood pressure. The predisposing factors include age, family history, quitting smoking, lack of sleep and certain medications. Treatment includes healthy lifestyle, medications and surgery.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Obesity – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Obesity (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Obesity (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Obesity and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 4, 16, 28, 125 and 27 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 57 and 13 molecules, respectively.

Obesity (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Obesity (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Obesity (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Obesity (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Obesity (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Obesity (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Obesity (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Obesity (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Table of Contents 2
Introduction 6
Obesity – Overview 7
Obesity – Therapeutics Development 8
Obesity – Therapeutics Assessment 36
Obesity – Companies Involved in Therapeutics Development 56
Obesity – Drug Profiles 98
Obesity – Dormant Projects 461
Obesity – Discontinued Products 476
Obesity – Product Development Milestones 480
Appendix 491

List of Tables
Number of Products under Development for Obesity, H2 2017 34
Number of Products under Development by Companies, H2 2017 36
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 37
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 38
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 39
Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017 40
Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017 41
Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017 42
Number of Products under Development by Universities/Institutes, H2 2017 43
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 45
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017 46
Products under Development by Companies, H2 2017 47
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 48
Products under Development by Companies, H2 2017 (Contd..2), H2 2017 49
Products under Development by Companies, H2 2017 (Contd..3), H2 2017 50
Products under Development by Companies, H2 2017 (Contd..4), H2 2017 51
Products under Development by Companies, H2 2017 (Contd..5), H2 2017 52
Products under Development by Companies, H2 2017 (Contd..6), H2 2017 53
Products under Development by Companies, H2 2017 (Contd..7), H2 2017 54
Products under Development by Companies, H2 2017 (Contd..8), H2 2017 55
Products under Development by Companies, H2 2017 (Contd..9), H2 2017 56
Products under Development by Companies, H2 2017 (Contd..10), H2 2017 57
Products under Development by Universities/Institutes, H2 2017 58
Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 59
Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017 60
Products under Development by Universities/Institutes, H2 2017 (Contd..3), H2 2017 61
Number of Products by Stage and Target, H2 2017 63
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 64
Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017 65
Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017 66
Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017 67
Number of Products by Stage and Target, H2 2017 (Contd..5), H2 2017 68
Number of Products by Stage and Target, H2 2017 (Contd..6), H2 2017 69
Number of Products by Stage and Mechanism of Action, H2 2017 71
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 72
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017 73
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017 74
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2 2017 75
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..5), H2 2017 76
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..6), H2 2017 77
Number of Products by Stage and Route of Administration, H2 2017 79
Number of Products by Stage and Molecule Type, H2 2017 81
Obesity - Pipeline by Abeome Corp, H2 2017 82
Obesity - Pipeline by Adamas Pharmaceuticals Inc, H2 2017 82
Obesity - Pipeline by Aegis Therapeutics LLC, H2 2017 83
Obesity - Pipeline by Akron Molecules AG, H2 2017 83
Obesity - Pipeline by Amgen Inc, H2 2017 83
Obesity - Pipeline by Antag Therapeutics ApS, H2 2017 84
Obesity - Pipeline by Aoxing Pharmaceutical Company Inc, H2 2017 84
Obesity - Pipeline by Arrowhead Pharmaceuticals Inc, H2 2017 85
Obesity - Pipeline by AstraZeneca Plc, H2 2017 85
Obesity - Pipeline by Athersys Inc, H2 2017 86
Obesity - Pipeline by Biophytis SAS, H2 2017 86
Obesity - Pipeline by BioRestorative Therapies Inc, H2 2017 87
Obesity - Pipeline by Biozeus, H2 2017 87
Obesity - Pipeline by Boehringer Ingelheim GmbH, H2 2017 88
Obesity - Pipeline by Braasch Biotech LLC, H2 2017 88
Obesity - Pipeline by C3J Therapeutics Inc, H2 2017 88
Obesity - Pipeline by Callitas Therapeutics Inc, H2 2017 89
Obesity - Pipeline by Carmot Therapeutics Inc, H2 2017 89
Obesity - Pipeline by Cereno Scientific AB, H2 2017 90
Obesity - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017 90
Obesity - Pipeline by CohBar Inc, H2 2017 91
Obesity - Pipeline by CoMentis Inc, H2 2017 91
Obesity - Pipeline by Connexios Life Sciences Pvt Ltd, H2 2017 91
Obesity - Pipeline by ConSynance Therapeutics Inc, H2 2017 92
Obesity - Pipeline by Corcept Therapeutics Inc, H2 2017 92
Obesity - Pipeline by Daiichi Sankyo Co Ltd, H2 2017 93
Obesity - Pipeline by DiscoveryBiomed Inc, H2 2017 93
Obesity - Pipeline by Eisai Co Ltd, H2 2017 94
Obesity - Pipeline by Eli Lilly and Co, H2 2017 94
Obesity - Pipeline by Eternygen GmbH, H2 2017 95
Obesity - Pipeline by Evotec AG, H2 2017 95
Obesity - Pipeline by FibroGen Inc, H2 2017 96
Obesity - Pipeline by Genmedica Therapeutics SL, H2 2017 96
Obesity - Pipeline by Gila Therapeutics Inc, H2 2017 96
Obesity - Pipeline by Gilead Sciences Inc, H2 2017 97
Obesity - Pipeline by GlaxoSmithKline Plc, H2 2017 97
Obesity - Pipeline by Glucox Biotech AB, H2 2017 98
Obesity - Pipeline by HanAll Biopharma Co Ltd, H2 2017 98
Obesity - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017 99
Obesity - Pipeline by Hyundai Pharmaceutical Co Ltd, H2 2017 99
Obesity - Pipeline by Immungenetics AG, H2 2017 100
Obesity - Pipeline by Intarcia Therapeutics Inc, H2 2017 100
Obesity - Pipeline by Ionis Pharmaceuticals Inc, H2 2017 101
Obesity - Pipeline by Ixchel Pharma LLC, H2 2017 101
Obesity - Pipeline by Johnson & Johnson, H2 2017 102
Obesity - Pipeline by Juno Therapeutics Inc, H2 2017 102
Obesity - Pipeline by Kissei Pharmaceutical Co Ltd, H2 2017 103
Obesity - Pipeline by Laboratorios Silanes SA de CV, H2 2017 103
Obesity - Pipeline by Lead Discovery Center GmbH, H2 2017 103
Obesity - Pipeline by Leading BioSciences Inc, H2 2017 104
Obesity - Pipeline by Lotus Pharmaceutical Co Ltd, H2 2017 104
Obesity - Pipeline by Magnus Life Ltd, H2 2017 105
Obesity - Pipeline by MedImmune LLC, H2 2017 105
Obesity - Pipeline by Merck & Co Inc, H2 2017 106
Obesity - Pipeline by Naia Ltd, H2 2017 106
Obesity - Pipeline by NeuroNano Pharma Inc, H2 2017 106
Obesity - Pipeline by NGM Biopharmaceuticals Inc, H2 2017 107
Obesity - Pipeline by NIBEC, H2 2017 107
Obesity - Pipeline by Nordic Bioscience A/S, H2 2017 108
Obesity - Pipeline by Novartis AG, H2 2017 108
Obesity - Pipeline by Novo Nordisk AS, H2 2017 109
Obesity - Pipeline by ObeTherapy Biotechnology, H2 2017 109
Obesity - Pipeline by Omeros Corp, H2 2017 110
Obesity - Pipeline by OPKO Biologics Ltd, H2 2017 110
Obesity - Pipeline by OPKO Health Inc, H2 2017 111
Obesity - Pipeline by Oramed Pharmaceuticals Inc, H2 2017 111
Obesity - Pipeline by Orexigen Therapeutics Inc, H2 2017 112
Obesity - Pipeline by Palatin Technologies Inc, H2 2017 112
Obesity - Pipeline by Pfizer Inc, H2 2017 113
Obesity - Pipeline by PharmaIN Corp, H2 2017 113
Obesity - Pipeline by Poxel SA, H2 2017 114
Obesity - Pipeline by Prometheon Pharma LLC, H2 2017 114
Obesity - Pipeline by ReCyte Therapeutics Inc, H2 2017 114
Obesity - Pipeline by Renova Therapeutics Inc, H2 2017 115
Obesity - Pipeline by Reviva Pharmaceuticals Inc, H2 2017 115
Obesity - Pipeline by Saniona AB, H2 2017 116
Obesity - Pipeline by Sanofi, H2 2017 116
Obesity - Pipeline by Seres Therapeutics Inc, H2 2017 117
Obesity - Pipeline by Shionogi & Co Ltd, H2 2017 117
Obesity - Pipeline by Sinil Pharmaceutical Co Ltd, H2 2017 118
Obesity - Pipeline by Sorrento Therapeutics Inc, H2 2017 118
Obesity - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017 119
Obesity - Pipeline by Toray Industries Inc, H2 2017 119
Obesity - Pipeline by Vicore Pharma AB, H2 2017 120
Obesity - Pipeline by Viking Therapeutics Inc, H2 2017 120
Obesity - Pipeline by Vivus Inc, H2 2017 121
Obesity - Pipeline by WhanIn Pharmaceutical Co Ltd, H2 2017 121
Obesity - Pipeline by XL-protein GmbH, H2 2017 122
Obesity - Pipeline by Yuyu Pharma Inc, H2 2017 122
Obesity - Pipeline by Zafgen Inc, H2 2017 123
Obesity - Pipeline by Zealand Pharma AS, H2 2017 123
Obesity - Dormant Projects, H2 2017 487
Obesity - Dormant Projects, H2 2017 (Contd..1), H2 2017 488
Obesity - Dormant Projects, H2 2017 (Contd..2), H2 2017 489
Obesity - Dormant Projects, H2 2017 (Contd..3), H2 2017 490
Obesity - Dormant Projects, H2 2017 (Contd..4), H2 2017 491
Obesity - Dormant Projects, H2 2017 (Contd..5), H2 2017 492
Obesity - Dormant Projects, H2 2017 (Contd..6), H2 2017 493
Obesity - Dormant Projects, H2 2017 (Contd..7), H2 2017 494
Obesity - Dormant Projects, H2 2017 (Contd..8), H2 2017 495
Obesity - Dormant Projects, H2 2017 (Contd..9), H2 2017 496
Obesity - Dormant Projects, H2 2017 (Contd..10), H2 2017 497
Obesity - Dormant Projects, H2 2017 (Contd..11), H2 2017 498
Obesity - Dormant Projects, H2 2017 (Contd..12), H2 2017 499
Obesity - Dormant Projects, H2 2017 (Contd..13), H2 2017 500
Obesity - Dormant Projects, H2 2017 (Contd..14), H2 2017 501
Obesity - Discontinued Products, H2 2017 502
Obesity - Discontinued Products, H2 2017 (Contd..1), H2 2017 503
Obesity - Discontinued Products, H2 2017 (Contd..2), H2 2017 504
Obesity - Discontinued Products, H2 2017 (Contd..3), H2 2017 505


List of Figures
Number of Products under Development for Obesity, H2 2017 34
Number of Products under Development by Companies, H2 2017 35
Number of Products under Development by Universities/Institutes, H2 2017 43
Number of Products by Top 10 Targets, H2 2017 62
Number of Products by Stage and Top 10 Targets, H2 2017 62
Number of Products by Top 10 Mechanism of Actions, H2 2017 70
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 70
Number of Products by Routes of Administration, H2 2017 78
Number of Products by Stage and Routes of Administration, H2 2017 78
Number of Products by Top 10 Molecule Types, H2 2017 80
Number of Products by Stage and Top 10 Molecule Types, H2 2017 80

【レポートのキーワード】

肥満

★調査レポート[肥満:治療薬開発パイプライン分析] (コード:GMDHC9914IDB)販売に関する免責事項を必ずご確認ください。
★調査レポート[肥満:治療薬開発パイプライン分析]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆